Hartford Funds Management Co LLC Increases Stake in Thermo Fisher Scientific Inc. (NYSE:TMO)

Hartford Funds Management Co LLC lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.2% in the 4th quarter, HoldingsChannel.com reports. The firm owned 1,132 shares of the medical research company’s stock after acquiring an additional 46 shares during the period. Hartford Funds Management Co LLC’s holdings in Thermo Fisher Scientific were worth $601,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Savant Capital LLC raised its position in shares of Thermo Fisher Scientific by 2.4% in the 4th quarter. Savant Capital LLC now owns 7,518 shares of the medical research company’s stock valued at $3,991,000 after purchasing an additional 175 shares during the last quarter. Alpha Cubed Investments LLC raised its position in Thermo Fisher Scientific by 7.0% during the 4th quarter. Alpha Cubed Investments LLC now owns 639 shares of the medical research company’s stock worth $339,000 after buying an additional 42 shares during the last quarter. MONECO Advisors LLC raised its position in Thermo Fisher Scientific by 41.0% during the 4th quarter. MONECO Advisors LLC now owns 994 shares of the medical research company’s stock worth $528,000 after buying an additional 289 shares during the last quarter. Compass Capital Management Inc. raised its position in Thermo Fisher Scientific by 7.6% during the 4th quarter. Compass Capital Management Inc. now owns 102,809 shares of the medical research company’s stock worth $54,570,000 after buying an additional 7,288 shares during the last quarter. Finally, Auxano Advisors LLC purchased a new position in Thermo Fisher Scientific during the 4th quarter worth approximately $202,000. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on TMO shares. Barclays raised their price target on shares of Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 25th. Robert W. Baird cut their target price on shares of Thermo Fisher Scientific from $621.00 to $620.00 and set an “outperform” rating for the company in a report on Thursday, April 25th. HSBC lifted their target price on shares of Thermo Fisher Scientific from $660.00 to $670.00 and gave the company a “buy” rating in a report on Tuesday. Evercore ISI lifted their target price on shares of Thermo Fisher Scientific from $575.00 to $610.00 and gave the company an “outperform” rating in a report on Thursday, April 4th. Finally, Citigroup assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 target price for the company. Five analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $607.35.

Insiders Place Their Bets

In other news, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $555.63, for a total transaction of $5,556,300.00. Following the transaction, the chief executive officer now owns 49,155 shares of the company’s stock, valued at approximately $27,311,992.65. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of the business’s stock in a transaction dated Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at approximately $7,250,362. The disclosure for this sale can be found here. Insiders have sold a total of 52,277 shares of company stock valued at $29,649,264 in the last 90 days. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock traded down $8.15 during trading on Tuesday, reaching $568.74. The company had a trading volume of 1,514,866 shares, compared to its average volume of 1,554,109. Thermo Fisher Scientific Inc. has a 1-year low of $415.60 and a 1-year high of $603.82. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The firm’s 50-day simple moving average is $574.58 and its 200 day simple moving average is $531.67. The firm has a market capitalization of $217.09 billion, a PE ratio of 36.48, a price-to-earnings-growth ratio of 2.41 and a beta of 0.80.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 24th. The medical research company reported $5.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The company had revenue of $10.35 billion for the quarter, compared to analysts’ expectations of $10.14 billion. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 21.56 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 15th. Shareholders of record on Friday, March 15th were paid a dividend of $0.39 per share. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s payout ratio is 10.01%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.